Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1

Related Experiment Video

Updated: Apr 16, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

Sun-Hyun Park1, Jae-Hyung Park1, Hye-Min Shim1

  • 1Department of Physiology & Obesity-mediated Disease Research Center, Keimyung University School of Medicine, Daegu, Republic of Korea.

Biochemical and Biophysical Research Communications
|March 12, 2015
PubMed

Insights

Short-term treatment with glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells from high glucose-induced apoptosis. This effect involves the PI3K/mTORC2/AKT pathway, suppressing FoxO-1 and preventing cell death in type 2 diabetes.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Cell Biology

Background:

  • Glucotoxicity significantly contributes to pancreatic beta-cell apoptosis in type 2 diabetes.
  • Glucagon-like peptide-1 (GLP-1) has shown potential in reducing beta-cell apoptosis.

Purpose of the Study:

  • To investigate the anti-apoptotic mechanisms of GLP-1 against glucotoxicity.
  • To determine if short-term GLP-1 treatment protects beta-cells from glucotoxicity-induced apoptosis.

Main Methods:

  • Short-term GLP-1 treatment (30 minutes) applied to beta-cells.
  • Analysis of phosphoinositide 3-kinase (PI3K)/AKT-S473 phosphorylation and FoxO-1 suppression.
  • Selective inactivation of mTOR complex 2 (mTORC2) using small interfering RNA (siRNA).

Main Results:

  • GLP-1 treatment significantly alleviated high glucose-induced beta-cell apoptosis.
  • GLP-1's effect was linked to PI3K/AKT-S473 phosphorylation and subsequent FoxO-1 suppression.
  • Inactivation of mTORC2 abolished GLP-1's protective effects and FoxO-1 suppression.

Conclusions:

  • The protective effect of GLP-1 against glucotoxicity is mediated by FoxO-1 suppression via the PI3K/mTORC2/AKT-S473 pathway.
  • Short-term GLP-1 administration offers a beneficial protective strategy against glucotoxicity-induced beta-cell apoptosis.
Keywords:
FoxO-1Glucagon-like peptide-1GlucotoxiciyPancreatic β-cellType 2 diabetesmTOR complex 2

More Related Videos

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

11.8K
Intraportal Transplantation of Pancreatic Islets in Mouse Model09:01

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

10.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.2K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
9.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995